← Leaderboards
Aprile L Pilon
Claragen, Inc.
$2,486,340
Attributed
$2,486,340
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $375K · FY2007–23$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,486,340 · 8
By mechanism
R44$1,499,750 · 2
R43$886,625 · 5
R41$99,965 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsCellsReactionIn VitroProductionIn VivoPreparationPreventVaccinesScale UpKilogramChitinComplexCostChimeric ProteinsChromatographyLengthBioprocessBiodefenseIndustryBiological ProductsBiomedical ResearchChemical SynthesisInsulin
Grant awards (9)
Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction$260,664
R43 · FY2023 · HL · contact PI
Role of Secretoglobin 1A1 Protein in COVID-19-induced Thrombosis$256,467
R43 · FY2021 · HL · contact PI
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept$375,000
R44 · FY2010 · GM · contact PI
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept$375,000
R44 · FY2009 · GM · contact PI
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept$169,501
R43 · FY2007 · GM · contact PI
Recombinant CC10 for treatment of meconium aspiration$100,000
R43 · FY2003 · HL
Optimum Dose of rhCC10 for Lung Protection in IRDS$99,965
R41 · FY2001 · HL
RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD$749,750
R44 · FY2000 · HL
RECOMBINANT HUMAN CC10 AND NOTCH-1 ANTAGONIST IN NSCLC$99,993
R43 · FY2000 · CA